RESVERATROL SUPPLEMENTATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PROSPECTIVE, OPEN LABEL, RANDOMIZED CONTROLLED TRIAL

Abstract

Resveratrol has been reported for its wide ranging beneficial effects on the biological system. The objective of the present study was to evaluate the effect of oral supplementation of resveratrol in patients with type 2 diabetes mellitus. A prospective, open label, randomized controlled trial was, therefore, conducted at Government Headquarters Hospital, Ootacamund, India, in which sixty two patients with T2DM were enrolled. Patients were randomized into control and intervention groups. The control group received only oral hypoglycemic agents whereas the intervention group received resveratrol (250 mg / day) along with oral hypoglycemic agents for a period of six months. HbA1C, lipid profile, oxidative stress, urea nitrogen, creatinine and protein were measured at the base line and at the end of six months. Of the 62 recruited subjects, 57 completed the study, namely 29 patients in the control group and 28 patients in the intervention group. The results reveal that supplementation of resveratrol for six months significantly decreases body weight, systolic blood pressure, total cholesterol, triglyceride, urea nitrogen and total protein. Significant increase in the level of antioxidant enzymes, namely superoxide dismutase, catalase, reduced glutathione was also observed, in addition to significant decrease in the lipid peroxidation. Resveratrol also decreases the levels of HbA1c and fasting blood glucose. However, these changes were not statistically significant. Resveratrol supplementation in patients with T2DM is found to be effective in improving associated vascular risk factors and glycemic control. Resveratrol could, therefore, be used as an effective adjuvant therapy with a conventional hypoglycemic regimen for the management of diabetes.